First-in-class theranostics for the diagnosis and treatment of fibrosis
Many established or experimental drugs may silence activated myofibroblasts - the cells that drive fibrosis. However, many of these drugs produce severe side-effects in non-target tissues, while others may not be able to reach the myofibroblasts at all. We aim to unlock the potential of such molecules, by delivering them to the myofibroblasts in a smart, targeted way.
We employ a small team of dedicated scientists with broad experience in targeted drug delivery. Within the Amsterdam UMC Imaging Center, they have access to state-of-the art facilities including radioactive tracer production facilities, chemical- and biochemical laboratories, preclinical facilities, and preclinical- and clinical Imaging equipment (PET/CT, PET/MRI).
Share this article